Alzheimer's Biotech Targets $125M IPO
Clinical-stage drug maker vTv Therapeutics Inc. set terms for a $125 million initial public offering Monday, laying the groundwork for the summer's second debut of an Alzheimer's disease treatment developer....To view the full article, register now.
Already a subscriber? Click here to view full article